Amgen’s (AMGN) blinatumomab was granted FDA orphan designation as a treatment of acute lymphoblastic leukemia, according to a post to the agency’s ...
Officially lowering the evidentiary bar creates a predictable risk: more companies may highlight their most favorable study while downplaying or withholding less supportive results -- data the public ...
Only 6% of trials for FDA-approved drugs match America's diversity. Analysis reveals how trial location and design choices ...
The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback